Medi Assist

medibuddy.in →

-16%

est. 2Y upside i

HealthcareSeries C

Rank

#2670

Sector

HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Medium

The expected equity upside over 2 years is -15.9%, driven by a $420M secondary valuation and $218.5M preference overhang.

Last updated: July 3, 2026

Bull (10%)+100%

If IPO window opens and MediBuddy achieves category leadership, multiple expands to 4.6x forward revenue, resulting in a total exit value of $1.058B and common stock doubling after preference liquidation.

Base (45%)+12%

Multiple converges to 3x forward revenue, exit value $690M, common stock gains 12.3% after preference, as revenue grows to $230M.

Bear (45%)-70%

Multiple compresses to 1.5x due to incumbent competition, exit value $345M, common stock loses 69.9% after preference liquidation ($218.5M).

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

52%

$218.5M in preferred liquidation preference against $420M common valuation (52% overhang).

Dilution Risk

low

Company approaching profitability and considering IPO, so additional dilution is unlikely before liquidity event.

Secondary Liquidity

limited

Secondary market exists with recent implied value of $420M, but liquidity is limited to periodic transactions.

Questions to Ask at the Interview

Strategic questions based on Medi Assist's data — designed to show you've done your homework.

  • 1

    “How does MediBuddy plan to differentiate from Practo and Tata 1mg in the next 2 years?”

  • 2

    “What are the unit economics and churn rates for B2B corporate clients vs B2C consumers?”

  • 3

    “Given the 52% preference overhang and IPO timeline, what is the realistic value of my equity under different exit scenarios?”

Community

Valuation Sentiment

Our model estimates -16% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.